LIMMATECH BIOLOGICS AG

SCHLIEREN, ZH

Unclaimed

Subcontracting experience

2 records from government sources. Past participation is not evidence of current teaming interest.

Role	Agency	Description	Vehicle	Obligated	Action date	Period
Subcontractor	Department of Health and Human Services	STAPHYLOCOCCUS AUREUS (SA), CAUSES SERIOUS DISEASES INCLUDING BLOOD STREAM INFECTION, SEPSIS, ENDOCARDITIS, SURGICAL SITE INFECTIONS (SSI), AND PNEUMONIA. METHICILLIN RESISTANT SA (MRSA) IS CURRENTLY A LEADING CAUSE OF THESE LIFE THREATENING INFECTIONS WITH LIMITED OPTIONS FOR TREATMENT. FOUR VACCINE AND IMMUNOTHERAPEUTIC APPROACHES TARGETING SA SURFACE ANTIGENS HAVE BEEN TESTED IN EFFICACY TRIALS IN HUMANS AND ALL HAVE FAILED. ONE OF THESE VACCINES (V710) CAUSED MULTI-ORGAN FAILURE IN VACCINATED INDIVIDUALS WHO WERE INFECTED WITH SA LEADING TO TRIAL TERMINATION BY FDA. STUDIES IN ANIMALS HAVE ALSO SHOWN THAT VACCINES TARGETING SURFACE ANTIGENS INCREASE THE RISK OF DEATH FROM SA INFECTION. THIS PROJECT SEEKS TO DEVELOP A NOVEL, ENTIRELY TOXOID BASED VACCINE (LTB-SA7) FOR PREVENTION OF MRSA INFECTIONS. LTB-SA7 CONSISTS OF FIVE COMPONENTS REPRESENTING TOXOIDS FOR SIX SA TOXINS. DUE TO CROSS REACTIVITY, THESE TOXOIDS ELICIT PROTECTIVE RESPONSES TO 12-15 SA TOXINS. EFFICACY OF THE LTB-SA7 COMPONENTS HAS BEEN SHOWN IN VARIOUS MOUSE AND RABBIT MODELS OF INFECTION. THIS IS THE FIRST ENTIRELY NON-SURFACE ANTIGEN BASED VACCINE FOR SA DISEASE. THE STUDIES COMPLETED UNDER CARB-X SUPPORT PRECLINICAL ACTIVITIES, GMP MANUFACTURING AND IND ACTIVATION, AND ENTER INTO A PHASE I CLINICAL TRIAL. FOLLOWING THIS FUNDING PERIOD, LIMMATECH BIOLOGICS AG INTENDS TO TEST THE VACCINE IN PHASE II AND PHASE III CLINICAL TRIALS FOR PREVENTION OF SSTI IN RECURRENT SA SKIN INFECTIONS AND LATER IN SSI IN ELECTIVE SURGERIES. A TEAM OF EXPERIENCED SCIENTISTS AND PROGRAM MANAGERS AT LIMMATECH BIOLOGICS AG WILL LEAD THE PROGRAM. WORLD EXPERTS AND COLLABORATORS IN THE FIELD OF SA WILL COLLABORATE WITH LIMMATECH BIOLOGICS AG ON THIS PROJECT. KC3747 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541714 Parent award performance state: MA Parent award description: CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA View parent award on USAspending	—	$2,572,172	Mar 12, 2024	— – —
Subcontractor	Department of Health and Human Services	THE CONCURRENT RISE OF ANTIMICROBIAL RESISTANCE AND INCIDENCE OF SEXUALLY TRANSMITTED INFECTIONS IS A WORRYING COMBINATION. IN THE PAST DECADE, CASES OF GONORRHEA HAVE MORE THAN DOUBLED IN MANY COUNTRIES – IN THE US THERE ARE AN ESTIMATED 1.6 MILLION NEW INFECTIONS EACH YEAR, HALF OF WHICH ARE ANTIBIOTIC RESISTANT. OVER THE PAST 80 YEARS, NEISSERIA GONORRHOEAE, THE CAUSATIVE AGENT OF GONORRHEA, HAS STEADILY DEVELOPED RESISTANCE TO ALL ANTIMICROBIAL TREATMENTS. ALREADY TODAY, ONLY ONE RECOMMENDED TREATMENT OPTION REMAINS, AND FAILURES HAVE BEEN OBSERVED IN MULTIPLE COUNTRIES. GONORRHEA WILL CONTINUE TO DEVELOP RESISTANCE TO ANY NEW ANTIMICROBIALS, AND IN JUST A FEW YEARS UNTREATABLE DISEASE COULD BE WIDESPREAD. AN ALTERNATIVE SOLUTION IS URGENTLY NEEDED – A VACCINE. THERE ARE NO KNOWN EXAMPLES OF A PATHOGEN DEVELOPING RESISTANCE TO A VACCINE, AND ONLY LIMITED EXAMPLES OF EVASION BY SEROTYPE REPLACEMENT. BY PREVENTING INFECTIONS AND ILLNESS, ANTIBIOTIC PRESCRIPTIONS ARE REDUCED, AND SO IS DEVELOPMENT OF RESISTANCE. WIDESPREAD USE OF PNEUMOCOCCAL VACCINES HAS EVEN BEEN SHOWN TO SIGNIFICANTLY REDUCE CIRCULATING LEVELS OF RESISTANT BACTERIA. LIMMATECH BIOLOGICS AG IS DEVELOPING A VACCINE IS BASED ON A COMBINATION OF NOVEL ANTIGENS DELIVERED IN A NOVEL PRODUCTION PLATFORM. IMMUNE EVASION BY N. GONORRHOEAE MEANS THAT NATURAL INFECTION WITH THE PATHOGEN DOES NOT RESULT IN PROTECTIVE IMMUNITY, AND MANY GONOCOCCAL SURFACE ANTIGENS ARE HIGHLY VARIABLE IN STRUCTURE OR EXPRESSION, MAKING THEM POOR TARGETS FOR VACCINATION. OUR VACCINE IS DESIGNED TO OVERCOME THESE MECHANISMS BY AVOIDING PHASE VARIABLE STRUCTURES AND IMMUNOGENIC SURFACE DECOY ANTIGENS. ALL OUR ANTIGENS ARE HIGHLY CONSERVED BETWEEN STRAINS, INCLUDING RECENT AND RESISTANT CLINICAL ISOLATES, AND THIS, TOGETHER WITH THE MULTIVALENT DESIGN OF THE VACCINE MEANS COVERAGE IS EXPECTED TO BE 100%. ALL OUR ANTIGENS ARE HIGHLY IMMUNOGENIC IN PRECLINICAL STUDIES. THEY HAVE BEEN EXTENSIVELY VALIDATED USING A SET OF COMPLEMENTARY IN VITRO ASSAYS THAT DEMONSTRATE ANTIBODY FUNCTIONALITY AND PROTECTIVE MECHANISMS OF ACTION. THESE ASSAYS HAVE ALSO BEEN USED TO CONFIRM ANTIBODY FUNCTIONALITY AGAINST MULTIPLE STRAINS INCLUDING AMR CLINICAL ISOLATES. WE HAVE COMPLETED GMP PRODUCTION OF OUR VACCINE CANDIDATE, LTB-NG6, AND THE MATERIAL IS READY TO BE TESTED IN A FIRST-IN-HUMAN STUDY. WE HAVE SUBMITTED THE REGULATORY APPLICATION AND ARE AIMING TO START THIS PHASE I SAFETY AND IMMUNOGENICITY IN Q3 2026, AT A LOCATION IN GERMANY. KC3682 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541714 Parent award performance state: MA Parent award description: CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA View parent award on USAspending	—	$7,392,456	Dec 21, 2023	— – —

Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.

Government-sourced data comes from SAM.gov, SBA and USAspending.gov and is attributed to its source. Items marked company-reported were provided by the company and are verified by FedSub only where labeled. FedSub is a private company and is not affiliated with SBA, GSA/SAM.gov, or any government agency.